A polypeptide for preventing or treating idiopathic pulmonary fibrosis and a pharmaceutical composition containing the same

Abstract

The present invention relates to a polypeptide for preventing or treating idiopathic pulmonary fibrosis synthesized by connecting 9 to 10 amino acids, which comprises an amino acid sequence consisting of arginine (R, Arg, Arginine)-glycine (G, Gly, Glycine)-aspartic acid (D, Asp, Aspartic acid)-valine (V, Val, Valine)-phenylalanine (F, Phe, Phenylalanine)-proline (P, Pro, Proline)-serine (S, Ser, Serine)-tyrosine (Y, Tyr, Tyrosine)-threonine (T, Thr, Threonine). Through this, according to the polypeptide for preventing or treating idiopathic pulmonary fibrosis of the present invention, by fundamentally treating lung tissue that has undergone fibrosis due to idiopathic pulmonary fibrosis, lung function can be restored to normal levels, and further, idiopathic pulmonary fibrosis can be delayed or prevented.

Description

Technical Field

[0001] The present invention relates to a polypeptide for preventing or treating idiopathic pulmonary fibrosis and a pharmaceutical composition containing the polypeptide. Background Art

[0002] Idiopathic pulmonary fibrosis (IPF) is a fatal disease of unknown etiology characterized by recurrent inflammatory attacks in the interstitial lung tissue, which causes permanent scarring and tissue fibrosis, resulting in structural changes in the lung tissue, thereby reducing lung function and leading to death.

[0003] Idiopathic pulmonary fibrosis is a rare disease with unknown etiology. Its main symptoms are difficulty breathing during exercise, which becomes more severe as the symptoms progress. Due to lung inflammation and pulmonary fibrosis, the bronchi and lungs are irritated, resulting in a common symptom of dry cough.

[0004] Finally, if the difficulty breathing becomes more severe, not only will hypoxia occur, but also clubbing, where the tips of the fingers become arched.

[0005] Currently, although there is no recognized direct therapeutic agent that can effectively treat idiopathic pulmonary fibrosis, drugs called pirfenidone and nintedanib are currently in use. Although these drugs have been shown to be effective in slowing the progression of the disease, they have the limitation of not being able to completely cure it.

[0006] In addition, regarding the prior art of pharmaceutical compositions for treating idiopathic pulmonary fibrosis, the prior art document is Korean Registered Patent No. 10-1845862, "Pharmaceutical composition for treating or preventing idiopathic pulmonary fibrosis" (hereinafter referred to as "prior art").

[0007] However, the pharmaceutical compositions prepared in the past for the treatment of idiopathic pulmonary fibrosis, including the existing technology, have only partial therapeutic effects or very little effects, and are not significant. Therefore, there is a problem that they cannot provide a fundamental effect that can delay or treat the onset or progression of pulmonary fibrosis. Summary of the Invention

[0008] Problem to be solved

[0009] The present invention is proposed to solve the above-mentioned problems. The purpose of the present invention is to provide a polypeptide for preventing or treating idiopathic pulmonary fibrosis. By fundamentally treating the lung tissue that has undergone fibrosis due to idiopathic pulmonary fibrosis, the polypeptide can restore lung function to normal levels and further delay or prevent idiopathic pulmonary fibrosis.

[0010] Solutions to the Problem

[0011] In order to achieve the above-mentioned purpose, the polypeptide for preventing or treating idiopathic pulmonary fibrosis according to the present invention is synthesized by connecting 9 to 10 amino acids, including: an amino acid sequence consisting of arginine (R, Arg, Arginine) -glycine (G, Gly, Glycine) -aspartic acid (D, Asp, Aspartic acid) -valine (V, Val, Valine) -phenylalanine (F, Phe, Phenylalanine) -proline (P, Pro, Proline) -serine (S, Ser, Serine) -tyrosine (Y, Tyr, Tyrosine) -threonine (T, Thr, Threonine).

[0012] Wherein, the polypeptide for preventing or treating idiopathic pulmonary fibrosis can be selected from: a first polypeptide consisting of an amino acid sequence of arginine (R, Arg, Arginine)-glycine (G, Gly, Glycine)-aspartic acid (D, Asp, Aspartic acid)-valine (V, Val, Valine)-phenylalanine (F, Phe, Phenylalanine)-proline (P, Pro, Proline)-serine (S, Ser, Serine)-tyrosine (Y, Tyr, Tyrosine)-threonine (T, Thr, Threonine)-cysteine (C, Cys, Cysteine); a first polypeptide consisting of an amino acid sequence of arginine (R, Arg, Arginine)-glycine (G, Gly, Glycine)-aspartic acid (D, Asp, Aspartic acid) The second polypeptide consists of the amino acid sequence of arginine (R, Arg, Arginine)-glycine (G, Gly, Glycine)-aspartic acid (D, Asp, Aspartic acid)-valine (V, Val, Valine)-phenylalanine (F, Phe, Phenylalanine)-proline (P, Pro, Proline)-serine (S, Ser, Serine)-tyrosine (Y, Tyr, Tyrosine)-threonine (T, Thr, Threonine); the second polypeptide consists of the amino acid sequence of arginine (R, Arg, Arginine)-glycine (G, Gly, Glycine)-aspartic acid (D, Asp, Aspartic acid)-valine (V, Val, Valine)-phenylalanine (F, Phe, Phenylalanine)-proline (P, Pro, Proline)-serine (S, Ser, Serine)-tyrosine (Y, Tyr, Tyrosine)-threonine (T, Thr, Threonine); a third polypeptide consisting of the amino acid sequence of: arginine (R, Arg, Arginine)-glycine (G, Gly, Glycine)-aspartic acid (D, Asp, Aspartic acid); a third polypeptide consisting of the amino acid sequence of: arginine (R, Arg, Arginine)-glycine (G, Gly, Glycine)-aspartic acid (D, Asp, Aspartic acid); a third polypeptide consisting of the amino acid sequence of: arginine (R, Arg, Arginine)-glycine (G, Gly, Glycine)-aspartic acid (D, Asp, Aspartic acid); a fourth polypeptide consisting of the amino acid sequence of: amino acid)-valine (V, Val, Valine)-phenylalanine (F, Phe, Phenylalanine)-proline (P, Pro, Proline)-serine (S, Ser, Serine)-tyrosine (Y, Tyr, Tyrosine)-threonine (T, Thr, Threonine)-leucine (L, Leu, Leucine);One of the fifth polypeptides consisting of the amino acid sequence of Arginine (R, Arg, Arginine) - Glycine (G, Gly, Glycine) - Aspartic Acid (D, Aspartic Acid) - Valine (V, Val, Valine) - Phenylalanine (F, Phe, Phenylalanine) - Proline (P, Pro, Proline) - Serine (S, Ser, Serine) - Tyrosine (Y, Tyr, Tyrosine) - Threonine (T, Thr, Threonine) - Lysine (K, Lys, Lysine).

[0013] Furthermore, the polypeptide for preventing or treating idiopathic pulmonary fibrosis has a molecular weight of 1035 to 1200 Da, and the carboxyl group -COOH of the amino acid at the terminal end of the amino acid sequence constituting the polypeptide for preventing or treating idiopathic pulmonary fibrosis can be modified to -CONH2.

[0014] Furthermore, the polypeptide for preventing or treating idiopathic pulmonary fibrosis can reduce the expression of at least one of collagen and α-SMA (α-Smooth Muscle Actin) in the lung tissue of the subject being prevented or treated.

[0015] Furthermore, the polypeptide for preventing or treating idiopathic pulmonary fibrosis can be prepared into a dosage form for intralesional administration or intra-airway administration.

[0016] Furthermore, to achieve the above-mentioned object, the pharmaceutical composition for preventing or treating idiopathic pulmonary fibrosis according to the present invention contains the polypeptide for preventing or treating idiopathic pulmonary fibrosis having the above-mentioned characteristics as an active ingredient.

[0017] Furthermore, to achieve the above object, the present invention provides, in another aspect, a coding gene for encoding a polypeptide having the above characteristics for preventing or treating idiopathic pulmonary fibrosis.

[0018] Effects of the Invention

[0019] The effects of the present invention are as follows:

[0020] First, the polypeptide for preventing or treating idiopathic pulmonary fibrosis has the effect of reducing fibrosis indicators acting on idiopathic pulmonary fibrosis, thereby providing an effect of improving idiopathic pulmonary fibrosis.

[0021] Second, the polypeptide used to prevent or treat idiopathic pulmonary fibrosis can significantly reduce the expression of collagen and α-SMA (α-Smooth Muscle Actin), which are fibrosis indicators of lung tissue that are the target of idiopathic pulmonary fibrosis treatment.

[0022] Third, a polypeptide for preventing or treating idiopathic pulmonary fibrosis and a pharmaceutical composition containing the polypeptide can be provided, which has good biocompatibility, few side effects, is easy to mass-produce and easy to manage in quality.

[0023] Fourth, the polypeptide used to prevent or treat idiopathic pulmonary fibrosis not only provides a preventive or therapeutic effect on pulmonary fibrosis, but also can provide a preventive or therapeutic effect on similar diseases such as liver fibrosis and kidney fibrosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 A schematic diagram illustrating the process of preparing an animal experimental model designed to verify the effects of a polypeptide for preventing or treating idiopathic pulmonary fibrosis is shown;

[0025] Figure 2 and Figure 3 The figure shows the Ashcroft Score results in lung tissue of an animal experimental model designed to verify the effects of the polypeptide of the present invention for preventing or treating idiopathic pulmonary fibrosis;

[0026] Figure 4 and Figure 6 The figure shows the comparison results of the changes in α-SMA expression patterns in lung tissue of an animal experimental model designed to verify the effects of the polypeptide of the present invention for preventing or treating idiopathic pulmonary fibrosis;

[0027] Figure 7 and Figure 8 The figure shows the comparison results of changes in collagen expression patterns in lung tissue of an animal experimental model designed to verify the effects of the polypeptide of the present invention for preventing or treating idiopathic pulmonary fibrosis. DETAILED DESCRIPTION

[0028] The preferred embodiments of the present invention will be described in more detail with reference to the accompanying drawings. For the sake of brevity, some parts of the well-known technologies will be omitted or compressed.

[0029] 1. Description of polypeptides for preventing or treating idiopathic pulmonary fibrosis

[0030] Hereinafter, the synthesis process of the polypeptide for preventing or treating idiopathic pulmonary fibrosis according to the present invention and the structural characteristics of the synthesized peptide are described in detail.

[0031] According to the present invention, the polypeptide (Polypeptide) for preventing or treating idiopathic pulmonary fibrosis is prepared as a polypeptide synthesized by linking 9 amino acids or a polypeptide synthesized by linking 10 amino acids, according to an embodiment.

[0032] According to various embodiments, the sequence structure of the polypeptide synthesized by connecting 9 to 10 amino acids must at least contain an amino acid sequence consisting of arginine (R, Arg, Arginine) - glycine (G, Gly, Glycine) - aspartic acid (D, Asp, Aspartic acid) - valine (V, Val, Valine) - phenylalanine (F, Phe, Phenylalanine) - proline (P, Pro, Proline) - serine (S, Ser, Serine) - tyrosine (Y, Tyr, Tyrosine) - threonine (T, Thr, Threonine).

[0033] That is, the amino acid sequence consisting of 'RGDVFPSYT' as a motif, which has an RGD motif functional region, can be in the form of not only the corresponding sequence itself but also an amino acid added after the threonine (T) amino acid located at the very end thereof.

[0034] Specifically, five embodiments can be prepared, ranging from the first polypeptide to the fifth polypeptide, and although the amino acid sequences constituting each peptide have slightly different forms, the degree of preventive or therapeutic effect of idiopathic pulmonary fibrosis provided by them all show sufficient and significant results.

[0035] First, the first polypeptide is a peptide with the structure of 'RGDVFPSYTC' composed of the amino acid sequence of arginine (R, Arg, Arginine) - glycine (G, Gly, Glycine) - aspartic acid (D, Asp, Aspartic acid) - valine (V, Val, Valine) - phenylalanine (F, Phe, Phenylalanine) - proline (P, Pro, Proline) - serine (S, Ser, Serine) - tyrosine (Y, Tyr, Tyrosine) - threonine (T, Thr, Threonine) - cysteine (C, Cys, Cysteine), and its molecular weight is 1143Da to 1144Da (most preferably 1143.4Da).

[0036] Secondly, the second polypeptide is a peptide with the structure of 'RGDVFPSYT' composed of the amino acid sequence of arginine (R, Arg, Arginine) - glycine (G, Gly, Glycine) - aspartic acid (D, Asp, Aspartic acid) - valine (V, Val, Valine) - phenylalanine (F, Phe, Phenylalanine) - proline (P, Pro, Proline) - serine (S, Ser, Serine) - tyrosine (Y, Tyr, Tyrosine) - threonine (T, Thr, Threonine), and its molecular weight is 1139Da to 1140Da (most preferably 1139.9Da).

[0037] Furthermore, the third polypeptide is a peptide with the structure 'RGDVFPSYTR' consisting of the amino acid sequence of arginine (R, Arg, Arginine) - glycine (G, Gly, Glycine) - aspartic acid (D, Asp, Aspartic acid) - valine (V, Val, Valine) - phenylalanine (F, Phe, Phenylalanine) - proline (P, Pro, Proline) - serine (S, Ser, Serine) - tyrosine (Y, Tyr, Tyrosine) - threonine (T, Thr, Threonine) - arginine (R, Arg, Arginine), with a molecular weight of 1195 to 1197 Da (most preferably 1196 Da).

[0038] Furthermore, the fourth polypeptide is a peptide with the structure 'RGDVFPSYTL' consisting of the amino acid sequence of arginine (R, Arg, Arginine) - glycine (G, Gly, Glycine) - aspartic acid (D, Asp, Aspartic acid) - valine (V, Val, Valine) - phenylalanine (F, Phe, Phenylalanine) - proline (P, Pro, Proline) - serine (S, Ser, Serine) - tyrosine (Y, Tyr, Tyrosine) - threonine (T, Thr, Threonine) - leucine (L, Leu, Leucine), and has a molecular weight of 1152 to 1154 Da (most preferably 1153 Da).

[0039] Finally, the fifth polypeptide is a peptide with the structure of 'RGDVFPSYTK' composed of the amino acid sequence of arginine (R, Arg, Arginine) - glycine (G, Gly, Glycine) - aspartic acid (D, Asp, Aspartic acid) - valine (V, Val, Valine) - phenylalanine (F, Phe, Phenylalanine) - proline (P, Pro, Proline) - serine (S, Ser, Serine) - tyrosine (Y, Tyr, Tyrosine) - threonine (T, Thr, Threonine) - lysine (K, Lys, Lysine), with a molecular weight of 1168Da to 1169Da (most preferably 1168.2Da).

[0040] Among them, the polypeptide for preventing or treating idiopathic pulmonary fibrosis prepared by any one of the first to fifth polypeptide embodiments is synthesized using Solid Phase Peptide Synthesis according to a set sequence to achieve a purity of more than 90%.

[0041] As described above, the polypeptide for preventing or treating idiopathic pulmonary fibrosis prepared by any one of the first to fifth polypeptides with a purity of 90% or more can be confirmed to have a molecular weight of 1035 to 1200 Da by Mass Spectrometry.

[0042] Furthermore, in order to increase the absorption rate of the polypeptide for preventing or treating idiopathic pulmonary fibrosis prepared by any one of the first to fifth polypeptide embodiments, the carboxyl group -COOH of the amino acid at the terminal end of the amino acid sequence can be modified to -CONH2.

[0043] For example, the carboxyl group -COOH of the amino acid corresponding to 'C' in the first polypeptide, 'T' in the second polypeptide, 'R' in the third polypeptide, 'L' in the fourth polypeptide, and 'K' in the fifth polypeptide is modified to -CONH2, thereby improving the absorption rate.

[0044] The polypeptide for preventing or treating idiopathic pulmonary fibrosis according to the present invention can be used as the main active ingredient of a pharmaceutical composition for preventing or treating idiopathic pulmonary fibrosis.

[0045] Furthermore, the polypeptide for preventing or treating idiopathic pulmonary fibrosis according to the present invention and the pharmaceutical composition containing the polypeptide as the main active ingredient can be prepared into dosage forms for intralesional administration, intratracheal administration, intravenous administration or administration into specific tissues (lung tissue).

[0046] 2. Description of the results of the validation of the efficacy of peptides for the prevention or treatment of idiopathic pulmonary fibrosis

[0047] Regarding the polypeptides for preventing or treating idiopathic pulmonary fibrosis according to the present invention, the level of effect of the corresponding peptide in preventing or treating idiopathic pulmonary fibrosis was confirmed by testing. The purpose of the test is to define its properties by means obvious to those skilled in the art. For this purpose, the following experimental methods were used:

[0048] (1) Preparation and experimental design of idiopathic pulmonary fibrosis animal model

[0049] First, bleomycin was injected into 10-12 week old C57BL / 6 mice via tracheal instillation to create an acute idiopathic pulmonary fibrosis (IPF) induced animal model.

[0050] Specifically, 10-week-old C57BL / 6 mice were anesthetized with 2% isoflurane and mechanical ventilation. The mice were then placed with their mouths open and their tongues pointed forward to ensure the airway was visible. Bleomycin, a pulmonary fibrosis-inducing agent, was then administered at 2 mg / kg. (Methods Mol Biol. 2017;1627:27-42.)

[0051] Then, if Figure 1 As shown, after one week, mice with an acute idiopathic pulmonary fibrosis (Idiopathic Pulmonary Fibrosis) induced animal model were randomly selected and divided into a PBS-administered group (n=6) and a peptide-administered group (n=6, 100 μg / kg). 10-week-old C57BL / 6 mice (n=5) that did not induce acute specific fibrosis were classified as a normal control group (NC) (Negative control (n=6)) and were only administered with a vehicle.

[0052] Here, the animals were administered intratracheally with PBS (n=6) and peptide (n=6, 100 μg / kg) at a concentration of 100 μg / kg. (Am J Respir Crit Care Med. 2001 Jun; 163(7):1660-8)

[0053] At the same time, the peptides to be administered are administered in the form of the first polypeptide to the fifth polypeptide as described above and differentiated, so that the test results of each form can be compared.

[0054] Specifically, in the peptide administration group, the first polypeptide administration group is indicated by 'NPT-0021', the second polypeptide administration group is indicated by 'NPT-0022', the third polypeptide administration group is indicated by 'NPT-0023', the fourth polypeptide administration group is indicated by 'NPT-0024', and the fifth polypeptide administration group is indicated by 'NPT-0025'.

[0055] Secondly, after the substance is administered, on the third day, if Figure 1 Lung tissue was removed and subjected to the following histochemical analysis. The results of the evaluation and experimental methods described below are expressed as mean ± standard error (SEM). Statistical significance was determined using one-way analysis of variance (ANOVA), and post hoc verification was performed using the Scheffe method.

[0056] (2) Ashcroft Score of Idiopathic Pulmonary Fibrosis Animal Model

[0057] As described above, the evaluation was performed by dividing into three test groups, and the peptide administration groups were divided into the first to fifth polypeptide forms, and individual scoring results were derived.

[0058] After anesthetizing the animals in each experimental group, lung tissue was removed. Of the five lobes, one left lobe was removed and immediately placed in liquid nitrogen for protein extraction. The remaining four lobes were placed in a 4% paraformaldehyde (PFA) solution and refrigerated for one day. Paraffin blocks were then prepared, sectioned at 20 μm thickness using a Leica microtome, and mounted on silane-coated slides.

[0059] The lung tissue sections obtained in each test group were deparaffinized with Xylene and then dehydrated before H&E staining using a staining reagent equivalent to H&E Stain Kit (Hematoxylin and Eosin) (ab245880).

[0060] Then, the tissue sections were sealed with a cover glass using a mounting solution. The sections were stained and examined under a microscope (Nicon). Figure 2 The results shown in the figure are as follows. In order to evaluate the inflammatory response in lung tissue and the morphological characteristics and structural characteristics of alveolar cells, the Ashcroft Score was determined for immunohistochemical analysis. The derived results are as follows Figure 3 shown.

[0061] First, from Figure 2It was found that after induction of idiopathic pulmonary fibrosis, the degree of fibrosis could be compared between the group to which PBS was administered via the airway (IPFcontrol) and the group to which peptides were injected via the airway (NPT-0021 to NPT-0025).

[0062] As a result, through Figure 2 It was confirmed that all peptide-injected groups (NPT-0021 to NPT-0025) showed statistically significant improvements in the degree of fibrosis after induction of idiopathic pulmonary fibrosis.

[0063] The Ashcroft Score results implemented for data support, such as Figure 3 As shown in the figure, unlike the PBS-injected group (n=6), the Ashcroft scores of all peptide-injected groups (NPT-0021 to NPT-0025) were relatively low, indicating an improvement in the degree of pulmonary fibrosis (***P<0.0005, *P<0.05).

[0064] (3) Examination of Collagen and α-SMA Expression in Animal Models of Idiopathic Pulmonary Histiocytosis

[0065] Next, the animal models of each experimental group were anesthetized and the lung tissue was removed. Of the five lobes of lung tissue, one left lobe was kept in liquid nitrogen for protein extraction and sliced, lysed, and Western blotted. Figures 4 to 6 shown.

[0066] Specifically, the experiment conducted was to extract proteins from the left lobe of the lung using tissue lysis buffer in each individual of the group that was administered PBS via the airway (IPFcontrol) and the group that was injected with peptides via the airway (NPT-0021 to NPT-0025) after induction of idiopathic pulmonary fibrosis, in order to determine the extent of alpha smooth muscle actin (aSMA), a representative marker that increases during fibrosis induction.

[0067] In fact, if Figures 4 to 6 As shown, the group administered PBS via the airway (IPF control) had a higher amount of aSMA than the NC (Negative control (n=6)) control group, and the expression levels of aSMA in all peptide-injected groups (NPT-0021 to NPT-0025) were relatively reduced.

[0068] Yes, after anesthetizing the animal models of each test group, lung tissue was removed. Of the five lobes of lung tissue, except for one left lobe that was stored in liquid nitrogen for protein extraction, the remaining four lobes were placed in a 4% PFA (paraformaldehyde) solution and refrigerated for 1 day. Afterwards, paraffin blocks were prepared, sliced into 20 μm thickness using a Leica microtome, and attached to a silane-coated slide. After dehydration, immunofluorescence staining was performed using an antigen retrieval process to confirm the expression level of collagen. The results are as follows: Figure 7 shown.

[0069] Furthermore, the four lobes of the lung of each experimental group of animal models were sliced and attached with collagen antibodies to confirm the degree of collagen, one of the representative markers increased during fibrosis induction. The result curve of the digitized degree is shown in the figure below. Figure 8 shown.

[0070] Results, such as Figure 7 and Figure 8 As shown, the group administered PBS via the airway (IPF control) showed higher collagen expression compared to the NC (Negative control (n=6)) control group, whereas the collagen expression levels of all peptide-injected groups (NPT-0021 to NPT-0025) decreased.

[0071] In short, the polypeptide for preventing or treating idiopathic pulmonary fibrosis according to the present invention is prepared using one embodiment of the first to fifth polypeptides. Therefore, it is possible to significantly reduce the Ashcroft Score, which is an indicator of fibrosis affecting idiopathic pulmonary fibrosis, and the expression of Collagen and α-SMA (α-Smooth Muscle Actin), which are indicators of lung tissue fibrosis. This can fundamentally treat lung tissue that has undergone fibrosis due to idiopathic pulmonary fibrosis, restore lung function to normal levels, and further delay or avoid the onset of idiopathic pulmonary fibrosis.

[0072] The embodiments of the present invention are intended to illustrate the present invention and are not intended to limit the technical concepts of the present invention. The scope of the technical concepts of the present invention is not limited to such embodiments. It should be understood that the scope of protection should be interpreted according to the scope of the appended claims, and all technical concepts within the scope of the claims and their equivalents should fall within the scope of the present invention. <110> Nihil Co., Ltd. <120> A polypeptide for preventing or treating idiopathic pulmonary fibrosis and a pharmaceutical composition containing the same <130> LP21-039 <140> 10-2021-0083762 <141> 2021-06-28 <160> 5 <170> KoPatentIn 3.0 <210> 1 <211> 10 <212> PRT <213> Artificial sequence <220> <223> The first polypeptide for preventing or treating idiopathic pulmonary fibrosis <400> 1 Arg Gly Asp Val Phe Pro Ser Tyr Thr Cys 1 5 10 <210> 2 <211> 9 <212> PRT <213> Artificial sequence <220> <223> The second polypeptide for preventing or treating idiopathic pulmonary fibrosis <400> 2 Arg Gly Asp Val Phe Pro Ser Tyr Thr 1 5 <210> 3 <211> 10 <212> PRT <213> Artificial sequence <220> <223> The third polypeptide for preventing or treating idiopathic pulmonary fibrosis <400> 3 Arg Gly Asp Val Phe Pro Ser Tyr Thr Arg 1 5 10 <210> 4 <211> 10 <212> PRT <213> Artificial sequence <220> <223> The fourth polypeptide for preventing or treating idiopathic pulmonary fibrosis <400> 4 Arg Gly Asp Val Phe Pro Ser Tyr Thr Leu 1 5 10 <210> 5 <211> 10 <212> PRT <213> Artificial sequence <220> <223> The fifth polypeptide for preventing or treating idiopathic pulmonary fibrosis <400> 5 Arg Gly Asp Val Phe Pro Ser Tyr Thr Lys 1 5 10

Claims

1. A polypeptide for treating idiopathic pulmonary fibrosis, which is synthesized by linking 9 to 10 amino acids, characterized in that: The polypeptide for treating idiopathic pulmonary fibrosis is selected from: a first polypeptide consisting of the amino acid sequence of SEQ ID NO: 1; a second polypeptide consisting of the amino acid sequence of SEQ ID NO: 2; a third polypeptide consisting of the amino acid sequence of SEQ ID NO: 3; a fourth polypeptide consisting of the amino acid sequence of SEQ ID NO: 4; and a fifth polypeptide consisting of the amino acid sequence of SEQ ID NO:

5.

2. The polypeptide for treating idiopathic pulmonary fibrosis according to claim 1, characterized in that The carboxyl group -COOH of the terminal amino acid in the amino acid sequence constituting the polypeptide for treating idiopathic pulmonary fibrosis is modified to -CONH2.

3. Use of the polypeptide according to claim 1 in the preparation of a medicament for treating idiopathic pulmonary fibrosis, wherein: The polypeptide reduces the expression of at least one of collagen and α-SMA (α-Smooth Muscle Actin) in the lung tissue of the treated subject.

4. The use according to claim 3, characterized in that The polypeptide is prepared into a dosage form for intralesional administration, intratracheal administration or intravenous administration.

5. A pharmaceutical composition, characterized in that Contains the polypeptide for treating idiopathic pulmonary fibrosis according to claim 1 or 2 as an active ingredient.

6. A coding gene, characterized in that Encodes the polypeptide for treating idiopathic pulmonary fibrosis according to claim 1 or 2.

Images